Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension
- PMID: 16458092
- DOI: 10.1016/j.ophtha.2005.10.045
Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension
Abstract
Purpose: To compare 24-hour reduction in intraocular pressure (IOP) by latanoprost 0.005%, travoprost 0.004%, and bimatoprost 0.03% in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).
Design: Randomized, double-masked, crossover study.
Participants: Twenty-four patients with POAG and 20 with OH.
Methods: Patients were treated with latanoprost, travoprost, and bimatoprost for 1 month. The treatment sequence was randomized, and washout lasted 30 days for each trial drug. Four 24-hour tonometric curves were recorded for each patient: 1 at baseline and 1 after each treatment period.
Main outcome measures: Intraocular pressure was measured at 3, 6, and 9 am; noon; 3, 6, and 9 pm; and midnight by 2 treatment-masked well-trained evaluators using a handheld electronic tonometer with the patient in supine and sitting positions and a Goldmann applanation tonometer with the patient sitting at the slit lamp. Supine systemic blood pressure was recorded at the same times. A randomized-blocks analysis of variance was used to analyze data.
Results: All 3 drugs were highly effective in reducing IOP when compared to baseline. Mean IOP reductions were similar after the 3 prostaglandin analogs, and none of the differences among treatments reached statistical significance. The drugs' effect was significantly greater during the daytime (9 am-9 pm) than during the nighttime (midnight-6 am) with all prostaglandin analogs. In 7 of 44 patients (16%), nocturnal IOP was significantly higher than diurnal IOP, both at baseline and under the 3 prostaglandin analogs.
Conclusions: From a clinical point of view, the overall results seem to indicate that the 3 prostaglandin analogs are powerful agents in controlling round-the-clock IOP in POAG and OH patients.
Similar articles
-
Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2566-73. Invest Ophthalmol Vis Sci. 2000. PMID: 10937568 Clinical Trial.
-
Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.Ophthalmology. 2008 Jul;115(7):1117-1122.e1. doi: 10.1016/j.ophtha.2007.10.004. Epub 2008 Feb 20. Ophthalmology. 2008. PMID: 18082886
-
The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma.J Glaucoma. 2008 Jan-Feb;17(1):36-9. doi: 10.1097/IJG.0b013e318133fb70. J Glaucoma. 2008. PMID: 18303382 Clinical Trial.
-
A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.Curr Med Res Opin. 2007 Mar;23(3):601-8. doi: 10.1185/030079907X178720. Curr Med Res Opin. 2007. PMID: 17355741 Review.
-
Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma.Curr Med Res Opin. 2005 Nov;21(11):1875-83. doi: 10.1185/030079905X65600. Curr Med Res Opin. 2005. PMID: 16307709 Review.
Cited by
-
Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients.J Ophthalmol. 2018 Mar 7;2018:1319628. doi: 10.1155/2018/1319628. eCollection 2018. J Ophthalmol. 2018. PMID: 29707390 Free PMC article.
-
Switching efficacy on intraocular pressure from latanoprost to bimatoprost in eyes with open angle glaucoma: implication to the changes of central corneal thickness.Jpn J Ophthalmol. 2014 Sep;58(5):423-8. doi: 10.1007/s10384-014-0336-2. Epub 2014 Jul 9. Jpn J Ophthalmol. 2014. PMID: 25004992
-
Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.Clin Pharmacokinet. 2015 Jan;54(1):95-105. doi: 10.1007/s40262-014-0183-9. Clin Pharmacokinet. 2015. PMID: 25227284
-
The Benefit of Nocturnal IOP Reduction in Glaucoma, Including Normal Tension Glaucoma.Clin Ophthalmol. 2024 Nov 6;18:3153-3160. doi: 10.2147/OPTH.S494949. eCollection 2024. Clin Ophthalmol. 2024. PMID: 39525872 Free PMC article. Review.
-
Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension.Clin Ophthalmol. 2021 Oct 4;15:3997-4003. doi: 10.2147/OPTH.S333042. eCollection 2021. Clin Ophthalmol. 2021. PMID: 34675468 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical